@article{a3dc6a76c6d149f3b3cb745ecb2f7358,
title = "Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions",
abstract = "Type 2 diabetes mellitus is a progressive chronic disease and is an established risk factor for cardiovascular disease. Until recently, the cardiovascular safety and efficacy of antihyperglycemic drugs remained uncertain. However, after the changes in regulatory guidance in 2008, a wealth of data has been generated, expanding the focus of the treatment of diabetes from blood glucose control to the prevention of macro-and microvascular complications and improvement in mortality. This article will review cardiovascular outcome trials of antihyperglycemic agents and provide overview of ongoing trials.",
keywords = "Antihyperglycemic, Cardiovascular outcome trials, Type 2 diabetes mellitus",
author = "Kato, {Eri Toda} and Das, {Sandeep R.} and McGuire, {Darren K.}",
note = "Funding Information: Declaration of Competing Interest: ETK reports personal fees from Daiichi Sankyo, AstraZeneca, Bristol-Myers Squibb, and Tanabe-Mitsubishi Pharma, as well as grants and personal fees from Ono Pharmaceutical. SRD has nothing to disclose. DKM discloses the following relationships: personal fees for clinical trial leadership from GlaxoSmithKline, Janssen, Lexicon, AstraZeneca, Sanofi Aventis, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Eisai Inc., Esperion, Lilly USA; and personal fees for consultancy from AstraZeneca, Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Metavant, Applied Therapeutics, Sanofi Aventis, Afimmune. Publisher Copyright: {\textcopyright} 2020",
year = "2021",
month = feb,
doi = "10.1016/j.tcm.2019.12.010",
language = "English (US)",
volume = "31",
pages = "101--108",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",
number = "2",
}